LIPUM
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. Lipum has a biological anti-inflammatory drug candidate developed against Rheumatoid Arthritis (RA) – an autoimmune disease characterized by chronic inflammation of the joints. It often causes disability and lowers the quality of life for millions. Lipum also addresses the treatment of Juvenile Idiopathic Arthritis (JIA) that is a rare disease affecting children. A nove... l biological drug for this disease may be considered for an orphan drug designation. Treatment of other chronic inflammatory conditions is also explored. Related diseases are such as Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis. Lipum's biological anti-inflammatory drug candidate provides a novel mechanism of action. Therefore, it is assumed to have less adverse effects than current treatments in use.
LIPUM
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2010-01-01
Address:
Umeå, Vasterbottens Lan, Sweden
Country:
Sweden
Website Url:
http://www.lipum.se
Total Employee:
1+
Status:
Active
Contact:
+46 90 340 34 30
Email Addresses:
[email protected]
Total Funding:
351.19 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon WordPress Wordpress Plugins Nginx Sitelinks Search Box
Current Employees Featured
Founder
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - LipUm
Almi Invest
Almi Invest investment in Seed Round - LipUm
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-08 | Lipum has recruited Helena Bergström as Chief Medical Officer |
Official Site Inspections
http://www.lipum.se Semrush global rank: 4.73 M Semrush visits lastest month: 2 K
- Host name: 252.254.228.35.bc.googleusercontent.com
- IP address: 35.228.254.252
- Location:
- Latitude: 47
- Longitude: 8
- Timezone: Europe/Vaduz
More informations about "LipUm"
About Lipum AB (publ)
Feb 26, 2025 Lipum is also evaluating other inflammatory diseases with significant unmet medical needs. Lipum’s office and a laboratory reside within Uminova Science Park in Umeå. …See details»
Lipum - We develop an anti-inflammatory drug with …
Lipum AB (publ) was originally founded based on a discovery made by scientists at Umeå University. The history of the innovation goes back to the 1970s when Olle Hernell, Prof. of Pediatrics and his group was studying breast milk and …See details»
Lipum - utveckling av antiinflammatoriska läkemedel
Apr 11, 2025 Lipum har genomfört en klinisk fas 1-studie. D en kliniska studierapporten (CSR) har slutförts och publicerats för bolagets First-in-Human (FIH) fas I-studie med SOL-116. Studien omfattade singeldoser i stigande …See details»
LIPUM AB - LinkedIn
LIPUM AB | 2,058 followers on LinkedIn. We have developed a biological drug SOL-116 for treatment of chronic inflammatory diseases | Lipum aims for better quality of life for the millions ...See details»
LipUm - Crunchbase Company Profile & Funding
Organization. LipUm . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Contact Email [email protected]; Phone Number +46 90 340 34 30; Lipum …See details»
Lipum AB (publ) (STO: LIPUM) Company Profile & Overview
Dec 30, 2024 Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL …See details»
Chairman on Lipum’s progress, vision, and challenges
Mar 17, 2025 BioStock reached out to Ingemar to gain insight into Lipum’s opportunities and how he can contribute to a successful transition from phase I to phase II for the drug candidate …See details»
Lipum’s COO brings track record in company building and ...
Apr 9, 2025 Lipum is developing the biological drug candidate SOL-116 for the treatment of chronic inflammatory diseases. SOL-116 has shown promising results in a phase I trial and is …See details»
A presentation of the Board of Directors for …
Board of Directors for Lipum AB. An experienced management team for development of Lipums biological drug directed towards the novel target molecule, ... & Commercial Officer (CCO) at …See details»
Lipum – a novel treatment of chronic inflammations - UBI
Aug 29, 2018 Lipum develops a biological pharmaceutical for a novel mechanism of action in the treatment of chronic inflammations. The lead candidate drug (SOL-116) is a monoclonal …See details»
Lipum’s journey told by CSO and Co-founder - BioStock
Feb 16, 2023 Lipum was founded in 2010 after exciting discoveries. After further studies on the pro-inflammatory function of BSSL, the research group realised that the inflammation can be …See details»
Double celebration for Lipum - BioStock
Feb 6, 2025 In an interview with BioStock, Hernell reflects on Lipum’s journey – from its academic research origins to becoming a publicly traded company developing a novel biologic …See details»
Lipum: Livskvalitet med kroniska inflammatoriska sjukdomar
Feb 26, 2025 Lipum AB (publ) är ett biofarmaceutiskt bolag i klinisk fas specialiserat på upptäckt och utveckling av ny behandling för kroniska inflammatoriska sjukdomar. …See details»
Lipum AB - Allt om företaget, aktien, nyemissioner och notering
Lipum säkerställer ytterligare finansiering genom ett lånelöfte på 20 Mkr från ägaren Flerie Invest. maj 6, 2024 Lipums IPO får neutral rekommendation av Affärsvärldens analytikerSee details»
Industry case: With support from two SciLifeLab service areas, …
Sep 8, 2023 Services. Overview Services provided by our national research infrastructure; Find services Find the right technology or expertise for your research project; Recent user …See details»
Lipum has entered a partnership with QPS Netherlands
Mar 9, 2022 Web: www.lipum.se. About QPS HOLDINGS, LLC. Founded in 1995, QPS is a GLP/GCP-compliant contract research organization (CRO) and life sciences products supplier …See details»
BioStock: Chairman on Lipum’s progress, vision, and ... - Placera
Mar 17, 2025 BioStock reached out to Ingemar to gain insight into Lipum’s opportunities and how he can contribute to a successful transition from phase I to phase II for the drug candidate …See details»
Lipum AB (publ) Press Releases
Web: www.lipum.se. About QPS HOLDINGS, LLC. Founded in 1995, QPS is a GLP/GCP-compliant contract research organization (CRO) and life sciences products supplier supporting …See details»
Year-end report 2022 - Lipum AB (publ) Press Releases
Lipum AB (publ) has published the interim and the year-end report for 2022. Below is a summary, a complete report (only in Swedish) is available on the company's website. CEO Einar Pontén …See details»
Lipum’s CEO reflects on the year and comments on Eurostars …
Dec 19, 2024 Additionally, Lipum recently secured funding from Eurostars for a project with Age Labs, focused on predicting which patients are most likely to respond to the treatment. Lipum …See details»